--- title: "GLP-1 Receptor Agonists in ASUD Treatment" description: "A phase 2 RCT shows low-dose semaglutide reduces alcohol craving and heavy drinking with effect sizes exceeding naltrexone. What GLP-1 means for AUD treatment." date: 2025-11-21 updated: 2026-03-15 author: "Philipp D. Dubach" categories: - "Medicine" keywords: - "semaglutide alcohol use disorder" - "GLP-1 agonists addiction treatment" - "Ozempic alcoholism research" - "semaglutide vs naltrexone" - "new medications alcohol use disorder" - "GLP-1 alcohol craving" - "semaglutide AUD clinical trial" - "Ozempic reduce drinking" - "alcohol use disorder pharmacotherapy" - "GLP-1 receptor agonist reward pathway" - "semaglutide heavy drinking reduction" - "Wegovy alcohol" - "naltrexone vs semaglutide effect size" - "substance use disorder GLP-1" - "alcohol addiction medication 2025" - "dopamine signaling alcohol craving" - "pemvidutide alcohol use disorder" - "acamprosate disulfiram alternatives" - "off-label semaglutide alcohol" - "phase 2 trial semaglutide AUD" type: "Commentary" canonical_url: "https://philippdubach.com/posts/glp-1-receptor-agonists-in-asud-treatment/" source_url: "https://philippdubach.com/posts/glp-1-receptor-agonists-in-asud-treatment/index.md" --- # GLP-1 Receptor Agonists in ASUD Treatment *Philipp D. Dubach · Published November 21, 2025 · Updated March 15, 2026* ## Key Takeaways - A phase 2 RCT of 48 non-treatment-seeking adults reported that low-dose semaglutide reduced alcohol craving and heavy drinking episodes versus placebo, an unapproved indication in any jurisdiction. - Reported effect sizes for some drinking outcomes were broadly in the range published for naltrexone, one of three FDA-approved medications for alcohol use disorder, though direct head-to-head trials have not been conducted. - New AUD therapies have been approved at a rate of roughly one every 25 years, making the GLP-1 receptor agonist class an unusually active early-stage research area. --- > Alcohol and other substance use disorders (ASUDs) are complex, multifaceted, but treatable medical conditions with widespread medical, psychological, and societal consequences. However, treatment options remain limited, therefore the discovery and development of new treatments for ASUDs is critical. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), currently approved for the treatment of type 2 diabetes mellitus, obesity, and obstructive sleep apnea, have recently emerged as potential new pharmacotherapies for ASUDs. Semaglutide is one of several GLP-1 receptor agonists being studied as a candidate pharmacotherapy for alcohol use disorder, an indication for which it is not approved in any jurisdiction. People struggling with substance use disorders have few effective medication options. In February 2025, researchers at UNC published results from a randomized controlled trial of semaglutide in AUD. The phase 2 trial enrolled 48 non-treatment-seeking adults with AUD and administered low-dose semaglutide [over a nine-week titration schedule](https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2829811) below standard weight-loss dosing. Participants on semaglutide consumed less alcohol in controlled laboratory settings and reported fewer drinks per drinking day in their normal lives. They also reported less craving for alcohol. Heavy drinking episodes declined more sharply in the semaglutide group compared to placebo over the nine-week trial. The mechanism likely involves GLP-1 receptors in the brain's mesolimbic reward pathway, where the molecule modulates dopamine signaling to reduce the reinforcing effects of alcohol consumption. The reported effect sizes for some drinking outcomes were broadly in the range published for naltrexone, one of three FDA-approved AUD medications, but the studies are not head-to-head and the sample sizes are small. A [large real-world database study](https://www.nature.com/articles/s41467-024-48780-6) of 83,825 patients with obesity also found semaglutide associated with a 50-56% lower risk of AUD incidence and recurrence compared to other anti-obesity medications, an observational signal that needs prospective replication. Larger trials are needed to confirm these early results. Phase 3 trials evaluating semaglutide for AUD are now underway, and pemvidutide, a GLP-1/glucagon dual receptor agonist, has received FDA Fast Track designation for alcohol use disorder. *Related: [Ozempic is Reshaping the Fast Food Industry](https://philippdubach.com/posts/ozempic-is-reshaping-the-fast-food-industry/)* > **Disclaimer.** Journalism on health topics, not medical advice and not a substitute for consulting a qualified clinician. No clinician-patient relationship is created. [Full disclaimer](/disclaimers/#medical). > **Disclaimer.** Journalistic reportage on prescription-only medicines. Not advertising under HMG / HMR / HWG / FDA frameworks, not medical advice. Prescription and use require a qualified clinician. [Full disclaimer](/disclaimers/#pom). --- Canonical: https://philippdubach.com/posts/glp-1-receptor-agonists-in-asud-treatment/ This file is the canonical machine-readable variant of https://philippdubach.com/posts/glp-1-receptor-agonists-in-asud-treatment/. Author: Philipp D. Dubach (https://philippdubach.com/).